Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 47

1.

Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study.

Agius MA, Klodowska-Duda G, Maciejowski M, Potemkowski A, Li J, Patra K, Wesley J, Madani S, Barron G, Katz E, Flor A.

Mult Scler. 2017 Nov 1:1352458517740641. doi: 10.1177/1352458517740641. [Epub ahead of print]

PMID:
29143550
2.

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.

Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators.

Neurology. 2016 Nov 8;87(19):1985-1992. Epub 2016 Oct 12.

3.

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.

Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD.

Lancet Neurol. 2014 Jun;13(6):545-56. doi: 10.1016/S1474-4422(14)70049-3. Epub 2014 Mar 28. Erratum in: Lancet Neurol. 2013 Jun;13(6):536.

PMID:
24685276
4.

Mechanisms of action of ACTH in the management of relapsing forms of multiple sclerosis.

Berkovich R, Agius MA.

Ther Adv Neurol Disord. 2014 Mar;7(2):83-96. doi: 10.1177/1756285613518599. Review.

5.

Structural characterization of the main immunogenic region of the Torpedo acetylcholine receptor.

Morell SW, Trinh VB, Gudipati E, Friend A, Page NA, Agius MA, Richman DP, Fairclough RH.

Mol Immunol. 2014 Mar;58(1):116-31. doi: 10.1016/j.molimm.2013.11.005. Epub 2013 Dec 11. Erratum in: Mol Immunol. 2014 May;59(1):117.

PMID:
24333757
6.

Limited utility of current MRI criteria for distinguishing multiple sclerosis from common mimickers: primary and secondary CNS vasculitis, lupus and Sjogren's syndrome.

Kim SS, Richman DP, Johnson WO, Hald JK, Agius MA.

Mult Scler. 2014 Jan;20(1):57-63. doi: 10.1177/1352458513491329. Epub 2013 Jun 4.

PMID:
23736535
7.

Genome wide differences of gene expression associated with HLA-DRB1 genotype in multiple sclerosis: a pilot study.

Apperson ML, Tian Y, Stamova B, Ander BP, Jickling GC, Agius MA, Sharp FR.

J Neuroimmunol. 2013 Apr 15;257(1-2):90-6. doi: 10.1016/j.jneuroim.2013.02.004. Epub 2013 Mar 9.

PMID:
23477965
8.

Animal models of antimuscle-specific kinase myasthenia.

Richman DP, Nishi K, Ferns MJ, Schnier J, Pytel P, Maselli RA, Agius MA.

Ann N Y Acad Sci. 2012 Dec;1274:140-7. doi: 10.1111/j.1749-6632.2012.06782.x.

9.

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators.

Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1.

PMID:
23122650
10.

Sleepiness, fatigue, and risk of obstructive sleep apnea using the STOP-BANG questionnaire in multiple sclerosis: a pilot study.

Dias RA, Hardin KA, Rose H, Agius MA, Apperson ML, Brass SD.

Sleep Breath. 2012 Dec;16(4):1255-65. doi: 10.1007/s11325-011-0642-6. Epub 2012 Jan 21.

PMID:
22270686
11.

Acute severe animal model of anti-muscle-specific kinase myasthenia: combined postsynaptic and presynaptic changes.

Richman DP, Nishi K, Morell SW, Chang JM, Ferns MJ, Wollmann RL, Maselli RA, Schnier J, Agius MA.

Arch Neurol. 2012 Apr;69(4):453-60. doi: 10.1001/archneurol.2011.2200. Epub 2011 Dec 12.

12.

Accelerated central nervous system autoimmunity in BAFF-receptor-deficient mice.

Kim SS, Richman DP, Zamvil SS, Agius MA.

J Neurol Sci. 2011 Jul 15;306(1-2):9-15. doi: 10.1016/j.jns.2011.04.008. Epub 2011 May 6.

13.

Clinical and neuroimaging assessments for research studies (including drug trials) in multiple sclerosis.

Apperson ML, Agius MA.

Curr Protoc Neurosci. 2011 Jan;Chapter 10:Unit10.4. doi: 10.1002/0471142301.ns1004s54.

PMID:
21207365
14.

Differences in exon expression and alternatively spliced genes in blood of multiple sclerosis compared to healthy control subjects.

Tian Y, Apperson ML, Ander BP, Liu D, Stomova BS, Jickling GC, Enriquez R, Agius MA, Sharp FR.

J Neuroimmunol. 2011 Jan;230(1-2):124-9. doi: 10.1016/j.jneuroim.2010.09.001.

PMID:
20920832
15.

FMR1 premutation in females diagnosed with multiple sclerosis.

Zhang L, Coffey S, Lua LL, Greco CM, Schafer JA, Brunberg J, Borodyanskaya M, Agius MA, Apperson M, Leehey M, Tartaglia N, Tassone F, Hagerman PJ, Hagerman RJ.

J Neurol Neurosurg Psychiatry. 2009 Jul;80(7):812-4. doi: 10.1136/jnnp.2008.160960. No abstract available.

PMID:
19531693
16.

Current approved options for treating patients with multiple sclerosis.

Rizvi SA, Agius MA.

Neurology. 2004 Dec 28;63(12 Suppl 6):S8-14. Review.

PMID:
15623672
17.

An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis.

Vollmer TL, Phillips JT, Goodman AD, Agius MA, Libonati MA, Giacchino JL, Grundy JS.

Mult Scler. 2004 Oct;10(5):511-20.

PMID:
15471366
18.

Treatment of autoimmune myasthenia gravis.

Richman DP, Agius MA.

Neurology. 2003 Dec 23;61(12):1652-61. Review.

PMID:
14694025
19.

Treatment principles in the management of autoimmune myasthenia gravis.

Richman DP, Agius MA.

Ann N Y Acad Sci. 2003 Sep;998:457-72.

PMID:
14592915
20.

Three forms of immune myasthenia.

Agius MA, Richman DP, Fairclough RH, Aarli J, Gilhus NE, Romi F.

Ann N Y Acad Sci. 2003 Sep;998:453-6.

PMID:
14592914

Supplemental Content

Loading ...
Support Center